Related Experiment Video
Updated: Jul 29, 2026
06:04
Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
Published on: September 2, 2020
Effects of cannabinoids in Krox-24 targeted mice
E T Tzavara1, K Monory, S Garel
1INSERM U-99, Unité de Régulations des gènes et signalisation cellulaire, Hĵpital H. Mondor, Créteil, France.
Neuroreport
|June 5, 2001
Summary
Krox-24 is not involved in the acute analgesic effects of delta9-THC or cannabinoid withdrawal syndrome. This study used Krox-24 gene-targeted mice to investigate cannabinoid actions.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Krox-24, a zinc-finger transcription factor, is induced by cannabinoids.
- Its role in cannabinoid's central effects requires specific investigation.
Purpose of the Study:
- To dissect the role of Krox-24 in the acute and chronic central actions of cannabinoids.
- To evaluate behavioral and biochemical correlates of delta9-THC withdrawal.
Main Methods:
- Utilized Krox-24 gene-targeted mice and wild-type littermates.
- Assessed G-protein activation, adenylyl cyclase inhibition, and behavioral responses.
- Evaluated behavioral parameters and biochemical correlates of abstinence after delta9-THC withdrawal.
Main Results:
- Krox-24 is not involved in the acute analgesic effects of delta9-THC.
- Krox-24 does not play a role in the SR-precipitated delta9-THC withdrawal syndrome.
Conclusions:
- Krox-24 is dispensable for the acute central effects of delta9-THC and for cannabinoid withdrawal.
- Further research is needed to elucidate the specific adaptive responses mediated by Krox-24 in the context of cannabinoid signaling.
